DIA/FDA/Health Canada/AAPS/OTS

3rd Oligonucleotide-based Therapeutics Conference

Where Regulators and Industry Partner to Advance Oligonucleotide Science Together

March 23-25, 2010
DoubleTree Hotel and Executive Meeting Center
Bethesda, MD, USA

Co-sponsored by

FDA
Health Canada
American Association of Pharmaceutical Scientists
DIA
www.diahome.org
3rd Oligonucleotide-based Therapeutics Conference: Where Regulators and Industry Partner to Advance Oligonucleotide Science Together
March 23-25, 2010
DoubleTree Hotel and Executive Meeting Center
Bethesda, MD, USA

Keynote Speakers

Mauro Ferrari, PhD
Professor and Chairman, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston

Richard DiMarchi, PhD
Professor and Gill Chair in Biomolecular Science, Indiana University

CONFERENCE HIGHLIGHTS

Opening Plenary Session: The Challenges Faced and Accomplishments Made in the Development of Oligonucleotide-based Therapeutic Drugs
High-level dialogue to address the current challenges and emerging product development for oligonucleotide-based therapeutics from FDA, EU, Health Canada and Industry perspectives.

Two Keynote Speaker Sessions:

Mauro Ferrari, PhD
Professor and Chairman, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston

Richard DiMarchi, PhD
Professor and Gill Chair in Biomolecular Science, Indiana University

Closing Plenary Session: Panel Discussion and Path Forward
Regulators and Industry Align for the Next Generation of Oligonucleotide-based Therapeutics 2010

Join Industry and Regulatory Key Stakeholders from FDA and Health Canada to Share Product Development and Regulatory Information for Oligonucleotide-based Therapeutics.

This program was developed with the support of the Oligo Safety Working Group and the CMC Working Group.

Co-sponsored by
This conference will serve as a continuum for discussion among Industry and Health Authorities to inform, educate, and share oligonucleotide-based therapeutic product development and regulatory information in the areas of nonclinical, chemistry, manufacturing and control (CMC) and clinical development. These sessions will address targeted therapeutics and exploratory approaches of oligonucleotide-based therapeutic drugs, including bioinformatics, microRNAs, delivery, impurities and metabolism, thresholds and pre-clinical immune screenings prior to IND filing. Delivery technologies are of high priority to expand the therapeutic indications of oligonucleotide-based therapeutics and therefore this conference will also incorporate current dialogue to address RNA interference technologies and expand to the therapeutic segment to discuss emerging technologies for oligonucleotide science.

Who Should Attend
Chief Scientific Officers, Vice Presidents, Directors, Senior Management, Group/Team/Project Leaders, Scientists, Investigators and Researchers working in the following areas:

- Biotechnology
- Biologics
- Clinical research
- Chemistry, manufacturing, and control
- Clinical, regulatory, and business development
- Delivery technologies
- Drug discovery
- Preclinical
- Quality assurance
- RNAi
- Vaccines

Contact Information
Conference: Joanne Wallace, Program Manager, Phone 215.442.6180 / Fax 215.293.5931 / email Joanne.Wallace@diahome.org
CONFERENCE OBJECTIVES AND SESSION TOPICS

**Nonclinical**
The nonclinical sessions are designed to provide an opportunity to discuss the critical issues in oligonucleotide therapeutics and also to highlight efforts being made within the oligonucleotide community to address these issues. Some of the sessions are dedicated to technologies and other sessions provide a forum for discussing position papers prepared by scientists under the auspices of the Oligonucleotide Safety Working Group.

- Joint session to address CMC Issues and Impurities/theoretical discussion
- Off target effects and their assessment
- Delivery Issues and Oligonucleotides Therapeutics / Neuromuscular Indications
- New Technologies and Regulatory Requirements
- Oligonucleotide Safety Working Group (OSWG): Exaggerated Pharmacology Committee
- Immunostimulation Working Group
- Inhalation Working Group

**Chemistry, Manufacturing, and Controls (CMC)**
The CMC sessions will focus on a few of the issues that provide special challenges in development of synthetic oligonucleotides as compared to small molecules. Validation of analytical methods and the application of reporting, identification, and qualification thresholds to therapeutic oligonucleotides are prominent among these topics. We will hear about some of the latest developments in delivery technology, and we will consider if, after more than 20 years, we are ready for “sudden” success of therapeutic oligonucleotides. Many of the ideas from the first sessions will come together in a final session that looks in detail at drug substance specifications.

- Validation of Analytical Methods
- Novel Formulations
- Success
- Qualification Thresholds
- Reporting and ID Threshold Discussions
- Drug Substance Specifications

**Clinical Development**
The clinical sessions have been organized by disease indication to highlight the challenges faced, and accomplishments made, with oligonucleotide-based therapeutics to address unmet medical needs. Proof of concept data in humans using “naked” oligonucleotides will be presented in liver, hematologic, pulmonary, ophthalmic, oncology and neuromuscular diseases, while examples using delivery formulations will be provided in oncology and metabolic diseases. Talks will span programs ranging from early Phase I to post-NDA, and will cover synthetic siRNAs, antisense, aptamers, anti-miRs and immunostimulatory oligonucleotides.

- Liver/Metabolic Diseases
- Cardiorenal and Pulmonary
- Ophthalmics
- Oncology
- Vaccines
- Neuromuscular Indications

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice.

Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

CONTINUING EDUCATION CREDITS

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and Drug Information Association. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this educational activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Disclosure Policy:** It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosure will be included in the course materials.

To receive a certificate of credit you must complete both of the evaluation forms, both DIA and PIM

**LEARNING OBJECTIVES** At the conclusion of this meeting, participants should be able to:

- Identify oligonucleotide-based therapeutic product development challenges and the relevant FDA, EU and Health Canada regulations.
- Assess the challenges faced and the accomplishments made in the clinical development of oligonucleotide-based therapeutic drugs to meet unmet needs.
- Describe the critical issues in the nonclinical development of oligonucleotides.
- Outline efforts from industry and regulatory authorities to address critical issues in the nonclinical development of oligonucleotides.
- Differentiate the special challenges associated with the development of synthetic oligonucleotides as compared to small molecules.
- Assess special properties of oligonucleotide-based therapeutics that present special challenges in development including the scientific approaches to overcoming those challenges.
- Recognize achievements made in the field to date including the vision of potential benefits to patients.
**MONDAY, MARCH 22, 2010**

4:00-6:00 PM  CONFERENCE REGISTRATION

**DAY 1 | TUESDAY, MARCH 23, 2010**

7:30-8:45 AM  Conference Registration and Continental Breakfast

8:30-8:45 AM  WELCOME AND OPENING REMARKS

**David H. Schubert**
Vice President of Regulatory Affairs & Quality Assurance
Logical Therapeutics, Inc.

8:45-10:00 AM  SESSION 1: SPECIAL PLENARY SESSION

*The Challenges Faced and Accomplishments Made in the Development of Oligonucleotide-based Therapeutic Drugs*

**PLENARY DISCUSSANTS:**

- **S. Leigh Verbois, PhD**
  Supervisory Pharmacologist
  Division of Drug Oncology Products
  CDER, FDA

10:00-10:30 AM  REFRESHMENT BREAK

10:30-12:00 PM  SESSION 2

**Keynote Address: Introduction**

**Alan Sachs, MD, PhD**
Vice President, RNA Therapeutics
Merck Research Laboratories

**Keynote Speaker Presentation:**

**Mauro Ferrari, PhD**
Professor and Chairman, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston

12:00-1:30 PM  LUNCHEON AND NETWORKING OPPORTUNITY

1:30-3:00 PM  SESSION 3: CONCURRENT SESSIONS

**SESSION 3A: NONCLINICAL TRACK**

**EP/Genotox**

**Session Chairperson**

**Robert Dorsam, PhD**
Pharmacology/Toxicology Reviewer
CDER, FDA

- Exaggerated Pharmacology Subcommittee Report
- Douglas Kornbrust, PhD, DABT
  President and Scientific Advisory Board Member
  Preclinsight

- Genotoxicity Subcommittee Report
- Cindy Berman, PhD
  Independent Consultant

- Audience Questions and Discussion

**SESSION 3B: CMC TRACK**

**Validation of Analytical Methods**

**Session Chairperson**

**Ramesh Raghavachari, PhD**
Chemist
CDER, FDA

- Regulatory Perspective on Analytical Oligonucleotide Separations
  - Linda Ng, PhD
    CMC Lead
    CDER, FDA

- Challenges to Validation of Methods for Double-Stranded Oligonucleotide
  - Daren S. Levin, PhD
    Investigator
    Inhaled Product Development
    GlaxoSmithKline

- Validation of an HPLC-MS Impurities Method for LY2181308 Antisense Oligonucleotide
  - David Hollowell, PhD
    Research Advisor
    Eli Lilly and Company

- Audience Questions and Discussion

**SESSION 3C: CLINICAL TRACK**

**Liver/Metabolic Diseases**

**Session Chairperson**

**Diane Tribble, PhD**
Vice President, Clinical Development
Isis Pharmaceuticals, Inc.

- Mipomersen: Phase 3 Results in FH
- Patients
  - Diane Tribble, PhD
    Vice President, Clinical Development
    Isis Pharmaceuticals

- Phase I Evaluation of Stable Nucleic Acid Lipid Particles Containing Anti-ApoB siRNA
  - Ian MacLachlan, PhD
    Executive Vice President and Chief Scientific Officer
    Tekmira Pharmaceuticals Corporation

- microRNA Therapeutics: SPC3649 as a Case Study
  - Arthur A. Levin PhD
    Vice President and Chief Development Officer
    Santaris Pharma a/s

- Audience Questions and Discussion
## SESSION 4A: NONCLINICAL TRACK
### Emerging Technologies: Off-target Effects and Their Assessment

**SESSION CHAIRPERSONS**

Arthur A. Levin, PhD  
Vice President and Chief Development Officer  
Santaris Pharma a/s

Shwu-Luan Lee, PhD  
Pharmacology/Toxicology Reviewer  
CDER, FDA

**Assessing off Target Effects of siRNAs**  
Arthur M. Krieg, MD  
Chief Scientific Officer  
Research Technology Center  
Pfizer, Inc.

**Bioinformatics Approaches to Understanding Off-Target Effects of Allele Specific Oligonucleotide (ASO) and MicroRNAs**  
Morten Lindow, PhD  
Group Leader, Integrative Systems Biology  
MicroRNA Research  
Santaris Pharma A/S

**Presentation of the Oligonucleotide Safety Working Group (OSWG) Committee on Off-Targets**  
Arthur A. Levin, PhD  
Vice President and Chief Development Officer  
Santaris Pharma a/s

**Audience Questions and Discussion**

---

## SESSION 4B: CMC TRACK
### Novel Formulations

**SESSION CHAIRPERSON**

Anastasia Khvorova, PhD  
Chief Scientific Officer  
RXi Pharmaceuticals

**sd-rxRNA – Novel Class of Self-Delivering RNAi Compounds: Robust in vitro and in vivo Efficacy with Broad Clinical Potential**  
Anastasia Khvorova, PhD  
Chief Scientific Officer  
RXi Pharmaceuticals

**Making Drug Products Using Oligonucleotides**  
Keith Smith, PhD  
Alliance Project Director  
GlaxoSmithKline R&D  
United Kingdom

**Optimizing a Lipid-based Vehicle for siRNA Delivery to Liver**  
Paul A. Burke, PhD  
Executive Director  
RNA Therapeutics  
Merck & Co., Inc.

**Audience Questions and Discussion**

---

## SESSION 4C: CLINICAL TRACK
### Cardiorenal and Pulmonary

**SESSION CHAIRPERSON**

Akshay Vaishnaw, PhD, MD  
Senior Vice President, Clinical Research  
Alnylam Pharmaceuticals, Inc.

**Dose Escalation and Safety Study I5NP**  
Martin Polinsky, MD  
Executive Medical Director  
Cardio-Renal Program  
Quark Pharmaceuticals, Inc.

**RSV**  
Development of an RNAi Therapeutic for RSV  
Akshay Vaishnaw, PhD, MD  
Senior Vice President, Clinical Research  
Alnylam Pharmaceuticals

**Audience Questions and Discussion**

---

### NETWORKING RECEPTION

Join your colleagues from the conference at The Restaurant Oz, located at the foot of the spiral staircase in the lobby of the DoubleTree Hotel and Executive Meeting Center.
### SESSION 5A: NONCLINICAL TRACK

**Issues in Drug Delivery of Oligos**

**SESSION CHAIRPERSONS**

**Ian MacLachlan, PhD**
Executive Vice President and Chief Scientific Officer
Tekmira Pharmaceuticals Corporation

1. **Understanding the Delivery Issues for siRNA – An Introduction**
   **Ian MacLachlan, PhD**
   Executive Vice President and Chief Scientific Officer
   Tekmira Pharmaceuticals Corporation

2. **Pharmaceutical Development of a Novel Oligonucleotide Delivery Formulation**
   **Peter Jackson, PhD**
   Chief Operating Officer
   Medesis Pharma SA
   France

3. **Patrick Maurel, PhD**
   Chief Scientific Officer
   Medesis Pharma SA
   France

4. **Audience Questions and Discussion**

### SESSION 5B: CMC TRACK

**Success**

**SESSION CHAIRPERSON**

**Stephen Sofen, PhD**
Vice President
Operations Project/Product Management
Genzyme Corporation

1. **Evolution of a Peptide Contract Manufacturer**
   **Brian Gregg, MBA**
   Vice President
   Regulatory Affairs and Quality
   Bachem, Inc.

2. **Coping with the 2008-9 Global Acetonitrile Shortage – Thoughts of a Heavy User**
   **Peter McDonnell, PhD**
   Senior Technical Director
   Genzyme Corporation

3. **Attributes of Success: Development through Commercialization**
   **Tracy TreDenick**
   Head of Quality and Regulatory
   BioTechLogic, Inc.

4. **Audience Questions and Discussion**

### SESSION 5C: CLINICAL TRACK

**Ophthalmics**

**SESSION CHAIRPERSON**

**Nebojsa Janjic, PhD**
Chief Scientific Officer
SomaLogic

1. **Case History of the Development of Macugen**
   **Nebojsa Janjic, PhD**
   Chief Scientific Officer
   SomaLogic

2. **Development of PF-4523655 siRNA for AMD and DME**
   **Shai Erlich, PhD**
   Chief Medical Officer
   Quark Pharmaceuticals

3. **Development of QPI-1007 siRNA as a Neuroprotectant for NAION and Glaucoma**
   **James D. Thompson, PhD**
   Vice President, Pharmaceutical Development
   Quark Pharmaceuticals

4. **Audience Questions and Discussion**

---

**10:30-10:45 AM**

**HIGHLIGHTS FROM DAY 1**

---

**11:15 AM - 12:00 PM**

**SESSION 6**

**Keynote Address: Introduction**

**Andrew M. Vick, PhD**
Executive Vice President
Senior Director Pharmacokinetics, Dynamics and Metabolism
Seventh Wave Laboratories, LLC

**Keynote Speaker Presentation**

**The Emergence of Chemical Biotechnology as a means to Optimal Protein-based drugs**

**Richard DiMarchi, PhD**
Professor and Gill Chair in Biomolecular Science
Indiana University

---

**12:00-1:30 PM**

**LUNCHEON AND NETWORKING OPPORTUNITY**
SESSION 7A AND 7B: JOINT NONCLINICAL AND CMC TRACK

Qualification Thresholds: Joint CMC and Nonclinical Session

SESSION CHAIRPERSONS

Mamata De, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

Arthur A. Levin, PhD
Vice President and Chief Development Officer
Santaris Pharma a/s

Overview of Impurities in Synthetic Oligonucleotides
Daniel Capaldi, PhD
Vice President
Analytical and Process Development
Isis Pharmaceuticals, Inc.

Strategy for Evaluation and Qualification of Oligonucleotide Impurities:
A Toxicologist’s Perspective
Scott Henry, PhD, DABT
Vice President, PreClinical Development
Isis Pharmaceuticals, Inc.

Moderator for Audience Questions and Discussion
James McArdle, PhD
McArdle and Associates, Inc.

SESSION 7C: CLINICAL TRACK

Oncology
SESSION CHAIRPERSON

Robert Justice, MD
Director, Division of Drug Oncology Products (DDOP)
Office of Oncology Drug Products, Office of New Drugs
CDER, FDA

ALN-VSP02 in Liver Cancer
Jared Gollob, MD
Senior Director, Clinical Research
Alnylam Pharmaceuticals

Status of the Clinical Development of our Oligonucleotide Candidate Trabedersen (AP 12009)
Hubert Heinrichs, MD
Chief Medical Officer
Antisense Pharma

Lessons from the Clinical Development of Genasense
Loretta Itri, MD
President Pharmaceutical Development and Chief Medical Officer
Genta

SESSION 8A: NONCLINICAL TRACK

Immunostimulation Working Group

SESSION CHAIRPERSONS

Laine Peyton Myers, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

Rosanne M. Seguin, PhD
Associate Director Immunology and Development Support
Pharmaxis, Ltd

Discussion of the Complement Position Paper
Scott Henry, PhD, DABT
Vice President, PreClinical Development
Isis Pharmaceuticals, Inc.

Discussion of Toll-like Receptor (TLRS)
Arthur M. Krieg, MD
Chief Scientific Officer
Research Technology Center
Pfizer, Inc.

Investigations of Sequence Specific Toxicities of Antisense Oligonucleotides (ASOs)
Sebastien Burel, PhD
Associate Director, Preclinical Development
Isis Pharmaceuticals

SESSION 8B: CMC TRACK

Reporting and ID Threshold Discussions

SESSION CHAIRPERSON

James McArdle, PhD
McArdle and Associates, LLC.

PANEL DISCUSSANTS

Hüseyin Aygün, PhD
Chief Scientific Officer
BioSpring GmbH

Mamata De, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

Daniel Capaldi, PhD
Vice President
Analytical and Process Development
Isis Pharmaceuticals, Inc.

SESSION 8C: CLINICAL TRACK

Vaccines
SESSION CHAIRPERSON

Sukjoon Park, MD
Senior Director, Product Development
Emergent BioSolutions

Clinical experience with candidate malaria vaccines adjuvanted with CPG 7909 in US and Malian subjects
Ruth Ellis, MD, MPH
Head Clinical Group, Laboratory of Malaria, Immunology and Vaccinology
NIAID

Development of AV7909 next generation anthrax vaccine
Sukjoon Park, MD
Senior Director, Product Development
Emergent BioSolutions

Development of HEPLISAV, a 2-dose HBV vaccine containing ISS1018 TLR9 adjuvant
Tyler Martin, MD
Chief Medical Officer
Dynavax Technologies
SESSION 9A: NONCLINICAL TRACK
Inhalation Working Group Discussion

SESSION CHAIRPERSONS
Luqi Pei, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

Topigen’s Experience with Inhalation of Antisense Oligonucleotide Therapeutics
Paolo M. Renzi, MD, FCCP, FRCP
Chief Scientific Officer and Founder
Topigen Pharmaceuticals, Inc (Pharmaxis).

Exploiting the Potential of Therapeutic siRNAs for Pulmonary Diseases
Mark R. Edbrooke, PhD
Director, Respiratory Centre of Excellence for Drug Discovery
GlaxoSmithKline R&D, United Kingdom

Inhalation Subcommittee Report
Nicolay Ferrari, PhD
Director, Pharmacology
Pharmaxis, Ltd

FDA Perspective
Luqi Pei, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

Audience Questions and Discussion

SESSION 9B: CMC TRACK
Drug Substance Specifications

SESSION CHAIRPERSON
René Thürmer, PhD
Pharmaceutical Expert, Unit Pharmaceutical Biotechnology, BfArM – Federal Institute for Drugs and Medical Devices, Germany

PANEL DISCUSSANTS:
Kathryn L. Ackley, PhD
Director of Project Management
Girindus America, Inc.

Daniel Capaldi, PhD
Vice President, Analytical and Process Development
Isis Pharmaceuticals, Inc.

Daren S. Levin, PhD, MS
Investigator, Inhaled Product Development
GlaxoSmithKline R&D, United Kingdom

Ipsita Roymoulik, PhD
Analytical Development Group Leader
Avecia Oligomedicines

Bob Sharma, PhD, MBA
Vice President, Process Development & Manufacturing, Oncology
Geron Corporation

Fran Wincott, PhD
President
Wincott & Associates, LLC

Rao Kambhampati, PhD
Review Scientist
CDER, FDA

Audience Questions and Discussion

SESSION 9C: CLINICAL TRACK
Neuromuscular Indications

SESSION CHAIRPERSON
James Thompson, PhD
Vice President Pharmaceutical Development
Quark Pharmaceuticals

Barbara Wilcox, PhD
Pharmacology/Toxicology Reviewer
CDER, FDA

PANEL DISCUSSANTS
Giles Campion, MD, PhD
Chief Medical Officer and Vice President for Research & Development
Prosensa

Peter Sazani, PhD
Sr. Director Preclinical
AVI BioPharma, Inc.

Scott Henry, PhD, DABT
Vice President, Preclinical Development
Isis Pharmaceuticals, Inc.

Audience Questions and Discussion

10:00-10:30 AM REFRESHMENT BREAK
11:30-1:00PM  SESSION 10: PANEL DISCUSSION AND PATH FORWARD

Regulators and Industry Align for the Next Generation of Oligonucleotide-based Therapeutics 2010

This panel discussion will highlight the challenges and issues with the development of oligonucleotide-based products in general and as brought forth at this conference. The intention is to transform this discussion into action-oriented objectives to address the regulatory and industry issues and challenges affecting us all.

SESSION CO-MODERATORS

David H. Schubert  
Vice President of Regulatory Affairs and Quality Assurance  
Logical Therapeutics, Inc.

S. Leigh Verbois, PhD  
Supervisory Pharmacologist, Division of Drug Oncology Products  
CDER, FDA

PANELISTS

Paul Brown, PhD  
ODE Associate Director for Pharmacology and Toxicology  
CDER, FDA

Robert Kane, MD  
Acting Deputy Director  
Div of Medical Imaging and Hematology Products  
CDER, FDA

Arthur A. Levin, PhD  
Vice President and Chief Development Officer  
Santaris Pharma a/s

Celia Lourenco, PhD  
Manager Clinical Group I, Office of Clinical Trials  
Therapeutic Products Directorate  
Health Canada

James V. McArdle, PhD  
McArdle and Associates, LLC

James D. Thompson, PhD  
Vice President, Pharmaceutical Development  
Quark Pharmaceuticals, Inc.

René Thürmer, PhD  
Deputy Head Unit Pharmaceutical Biotechnology BfArM – Federal Institute for Drugs and Medical Devices, Germany

1:00 PM  CONFERENCE ADJOINED
REGISTRATION FORM
Register online or fax this page to +1.215.442.6199

DIA is a financially independent nonprofit, global, multidisciplinary association that provides a neutral forum for sharing information that optimizes the development and lifecycle management of biopharmaceutical and related products.

3rd Oligonucleotide-based Therapeutics Conference
Event #10010 • March 23-25, 2010
DoubleTree Hotel & Executive Meeting Center Bethesda, Bethesda, MD, USA

Contact Information
Event Information: Contact Joanne Wallace at the DIA office by telephone 215.442.6180, fax 215.293.5931 or email Joanne.Wallace@diahome.org.

Registration Fees
Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

<table>
<thead>
<tr>
<th>Industry Fee</th>
<th>US $1350</th>
</tr>
</thead>
<tbody>
<tr>
<td>Join DIA now to save on future events and to receive all the benefits of membership.</td>
<td>MEMBERSHIP US $140</td>
</tr>
<tr>
<td>Visit <a href="http://www.diahome.org/Membership">www.diahome.org/Membership</a></td>
<td></td>
</tr>
</tbody>
</table>

Discount Fees
Government (Full-time) US $ 405
Charitable Nonprofit/Academia (Full-time) US $ 675

PAYMENT OPTIONS: Register online at www.diahome.org or check payment method.

- **CREDIT CARD** number may be faxed to: +1.215.442.6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

  - Visa
  - MC
  - AMEX

Exp Date __________________________

Card # ____________________________

Name (printed) ____________________________

Signature ____________________________

- **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

- **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

Participants with Disabilities: DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.

TRAVEL AND HOTEL
The most convenient airport is Ronald Reagan National Airport and attendees should make airline reservations as early as possible to ensure availability. The DoubleTree Hotel & Executive Meeting Center Bethesda is holding a block of rooms at the reduced rate below until February 28, 2010, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

<table>
<thead>
<tr>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>$199</td>
<td>$199</td>
</tr>
</tbody>
</table>

Please contact the DoubleTree Hotel & Executive Meeting Center Bethesda by telephone at 301.664.7309 and mention the DIA event. The hotel is located at 8120 Wisconsin Avenue, Bethesda, MD 20814, USA.

CANCELLATION POLICY: On or before March 16, 2010

Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academy or Nonprofit (Member or Nonmember) = $100
Tutorial (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Please check the applicable category:

- Q Academia
- Q Government
- Q Industry
- Q CSO
- Q Student

(Call for registration information)

Last Name

First Name

Ml

Degrees

Q Dr.  Q Mr.  Q Ms.

Job Title

Company

Address (As required for postal delivery to your location)

Mail Stop

City

State

Zip/Postal

Country

Email Required for confirmation

Phone Number

Fax Number Required for confirmation